Work experience
Work experience
Studies working on and completed
- Astra-Zeneca Protocol No. D3251C00004 Phase III Asthma Study
- Behringer Ingelheim- Protocol No. 1218.22 Phase III Type 2 Diabetes
- Takeda–Protocol No. TMX67_301 Phase III Gout Study
- Boehringer Ingelheim- Protocol No. 1218.74 Phase III Type 2 Diabetes with Cardiovascular
- Bristol-Mayes- AstraZeneca- Protocol No. MB102-073 Phase III Type 2 Diabetes
- Merck-Protocol No. P06241/P202 Phase III Diabetes Type 2 Insulin
- Novartis Pharmaceuticals-Protocol No. CQAB149B2350 Phase IIIB COPD
- Novartis Pharmaceuticals-Protocol No. CQAB149B2351 Phase IIIB COPD
- Novartis Pharmaceuticals-Protocol No. CQMF149A2210 Phase II Persistent Asthma
- Novartis Pharmaceuticals-Protocol No. CQAB149B2349 Phase IIIB COPD February 2009 – Sept 2011
- Novartis Pharmaceuticals-Protocol No. CIGE025AUS33 Phase IV Asthma
- Forest Pharmaceuticals- Protocol No. LAS-MD-38 Phase III COPD
- Protocol no. CQMF149A2210 A randomized, multi-center, parallel group, double blind study to assess the safety of QMF Twist haler (500/400 µg) and mometasone furoate Twist haler (400 µg) in adolescent and adult patients with persistent asthma.
- Protocol no. CIGE025AUS33, A 26-week randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma.
- Protocol no. CQAB149B2351, A randomized, double-blind, controlled, parallel group, 12-weel treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18 µg once daily versus open label tiotropium 18 µg once daily in patients with moderate-to-severe COPD.
- Protocol no. CQAB149B2350, A 12-week treatment, multi-center, randomized, parallel group, blinded, double-dummy study to compare the efficacy and safety of indacaterol (150 µg o.d.) delivered via a SDDPI with Tiotropium (18 µg o.d.) delivered via a Hand haler, in patients with moderate-to-severe COPD.
- Protocol no. CQAB149B2349, A 12-week treatment, multi-center, randomized, parallel group, blinded, double-dummy study to access the superiority of indacaterol (150 µg o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50 µg bid) as an active comparator delivered via DISKUS.
- A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)
- A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause.
- A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects with Gout and Mild to Moderate Chronic Kidney Disease.
- FAVIPIRAVIR in COVID-19 Effect on viral shedding and disease progression.
- Appili Therapeutics Inc. Protocol Number: ATI0220
- Allena Pharmaceuticals, Inc. PROTOCOL ALLN-346-202
- National Institute of Allergy and Infectious Diseases ACTIV-2/A5401 (Adapt Out COVID 19)
- Astellas Pharma Global Development, Inc. (APGD) Protocol 2693-CL-0302
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
- Novartis Pharmaceutical- Phase II Constipation Study
- AstraZeneca-Protocol No. D3820C00008 Phase III Opioid-Induced Constipation
- Avexa Ltd-Protocol No. AVX-301 Phase 2b/3 HIV-1 Infected Patients
- Novartis Pharmaceuticals-Protocol No. CQAB149B2335S / Extension Phase II/III COPD
- Novartis Pharmaceuticals-Protocol No. CNVA237A2206 Phase II COPD
- Tap Pharmaceuticals Products, Inc.-Protocol No. F-GT06-153 Phase III Gout
- Novartis Pharmaceuticals-Protocol No. CQAB149B2338 Phase III COPD
- Novartis Pharmaceuticals-Protocol No. CQAB149B2346 Phase III COPD
- Organicell Protocol # BB-IND#19881 Phase 1 COVID-19 Study
- Genentech Protocol # MV40618 Baloxavir Marboxl for the reduction of direct transmission of Influenza.
- Bristol-Myers Squibb Research and Development Protocol 101-873 COVID-19 Treatment of Hospital Patient.
- Appili Therapeutics Inc. Protocol Number: ATI0220
- Allena Pharmaceuticals, Inc. PROTOCOL ALLN-346-202
- National Institute of Allergy and Infectious Diseases ACTIV-2/A5401 (Adapt Out COVID 19)
- Astellas Pharma Global Development, Inc. (APGD) Protocol 2693-CL-0302
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
- Novartis Pharmaceutical- Phase II Constipation Study
- AstraZeneca-Protocol No. D3820C00008 Phase III Opioid-Induced Constipation
- Avexa Ltd-Protocol No. AVX-301 Phase 2b/3 HIV-1 Infected Patients
- Novartis Pharmaceuticals-Protocol No. CQAB149B2335S / Extension Phase II/III COPD
- Novartis Pharmaceuticals-Protocol No. CNVA237A2206 Phase II COPD
- Tap Pharmaceuticals Products, Inc.-Protocol No. F-GT06-153 Phase III Gout
- Novartis Pharmaceuticals-Protocol No. CQAB149B2338 Phase III COPD
- Novartis Pharmaceuticals-Protocol No. CQAB149B2346 Phase III COPD
- Organicell Protocol # BB-IND#19881 Phase 1 COVID-19 Study
- Genentech Protocol # MV40618 Baloxavir Marboxl for the reduction of direct transmission of Influenza.
- Bristol-Myers Squibb Research and Development Protocol 101-873 COVID-19 Treatment of Hospital Patient.
- T2DM Device study
- T2DM Device & CVO study
- Rheumatoid Arthritis
- Atrial Fibrillation
- T2DM & CVOT study
- US/NIAID-Influenza Treatment in High-risk subjects
- US/NIAID-Influenza Treatment in Low-risk subjects
- Therapeutics Inc. – Obesity & cardiovascular
- Uncontrolled Asthma
- Moderate to Severe Vasomotor Symptoms (Hot Flashes)
- COPD
- Cohn’s Disease IBS
- Constipation Ulcerative Proctitis
- Insomnia Healthy Elderly Population
- Prevention of Menstrual Related Migraine
- Osteoarthritis of the Knee
- Phase I insomnia Studies
- Migraines
Work experience
Research Experiences
- GSK Anemia CKD
- Red Dress Diabetic Foot Ulcer
- Astellas OAB
- Constipation
- Type 2 DM Injection
- Gout
- Gout Renal Impairment
- Boca biolistic Observational Lupus and RA Studies
- Pfizer/PCSK9 Cardiovascular Risk Study
- Mundi Pharma BPH study
- Phase I- Diabetic Foot Ulcer Study
- HPV L1 Vaccine
- Pediatric Ear Infection
- Pediatric Asthma
- Merck/Pediatric Pneumonia Vaccines
- Stroke
- NASH
- Diabetic foot Ulcer Non-Heal
- Hanmi- T2 DM
- Watson Uterine Fibroids
- Constipation
- Type 2 DM Injection
- Gout Renal Impairment
- T2 DM Januvia Study
- T2DM Study
- Chronic Asthma
- Cardiovascular Study
- T2DM & Hypertension Monitoring.
- T2DM & MRI test.
- T2DM
- Lipid Study
- Flu Vaccine
- Treatment of Subjects with Overactive Bladder
- T2DM Device study
- T2DM Device & CVO study
- Rheumatoid Arthritis
- Atrial Fibrillation
- T2DM & CVOT study
- US/NIAID-Influenza Treatment in High-risk subjects
- US/NIAID-Influenza Treatment in Low-risk subjects
- Therapeutics Inc. – Obesity & cardiovascular
- Uncontrolled Asthma
- Moderate to Severe Vasomotor Symptoms (Hot Flashes)
- COPD
- Cohn’s Disease IBS
- Constipation Ulcerative Proctitis
- Insomnia Healthy Elderly Population
- Prevention of Menstrual Related Migraine
- Osteoarthritis of the Knee
- Phase I insomnia Studies
- Migraines
English 
Spanish